| Views | |
|---|---|
| Safety and immunogenicity of a modified vaccinia ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1 | 1063 |
| January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | |
|---|---|---|---|---|---|---|---|
| Safety and immunogenicity of a modified vaccinia ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1 | 8 | 5 | 0 | 6 | 5 | 12 | 5 |
| Views | |
|---|---|
| artconlli_a2015_mothe_beatriz_safety_immunogenicity.pdf | 1 |
| Views | |
|---|---|
| United States | 555 |
| Sweden | 107 |
| China | 74 |
| Germany | 52 |
| Ukraine | 41 |
| Spain | 31 |
| France | 29 |
| Canada | 21 |
| United Kingdom | 13 |
| Russia | 11 |
| Views | |
|---|---|
| Ashburn | 104 |
| Fairfield | 55 |
| Sunnyvale | 44 |
| Ann Arbor | 40 |
| Zhengzhou | 32 |
| Oakland | 31 |
| Mountain View | 30 |
| Beijing | 21 |
| Houston | 21 |
| Cambridge | 20 |